US FDA says no to Chelsea's Northera
This article was originally published in Scrip
Chelsea Therapeutics' stock sank in early trading on news that the US FDA has failed to approve its dizziness drug Northera (droxidopa). In February, Chelsea narrowly persuaded a panel of advisors to the FDA to back Northera (scripintelligence.com, 24 February 2012). The FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-4, with one abstention, in favour of approval.